Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Becton, Dickinson and Company stock logo
BDX
Becton, Dickinson and Company
$172.47
-0.6%
$186.95
$163.33
$251.99
$49.43B0.251.95 million shs3.45 million shs
DexCom, Inc. stock logo
DXCM
DexCom
$85.68
-1.1%
$76.38
$57.52
$118.80
$33.60B1.464.33 million shs2.07 million shs
Insulet Co. stock logo
PODD
Insulet
$305.66
-2.0%
$283.07
$173.00
$329.33
$21.51B1.37709,323 shs912,973 shs
ResMed Inc. stock logo
RMD
ResMed
$251.02
-0.5%
$232.85
$179.42
$263.05
$36.81B0.781.01 million shs976,773 shs
7 Stocks That Could Be Bigger Than Tesla, Nvidia, and Google Cover

Looking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Becton, Dickinson and Company stock logo
BDX
Becton, Dickinson and Company
0.00%+0.54%+3.74%-23.61%-27.91%
DexCom, Inc. stock logo
DXCM
DexCom
0.00%+0.83%+2.37%+22.55%-25.15%
Insulet Co. stock logo
PODD
Insulet
0.00%-3.92%+0.43%+31.52%+62.87%
ResMed Inc. stock logo
RMD
ResMed
0.00%+3.13%+2.91%+6.25%+19.61%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Becton, Dickinson and Company stock logo
BDX
Becton, Dickinson and Company
4.9765 of 5 stars
4.25.03.34.02.82.51.3
DexCom, Inc. stock logo
DXCM
DexCom
4.7633 of 5 stars
3.54.00.04.72.42.51.9
Insulet Co. stock logo
PODD
Insulet
4.1664 of 5 stars
2.43.00.04.93.30.81.9
ResMed Inc. stock logo
RMD
ResMed
4.029 of 5 stars
2.31.03.34.62.31.71.3
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Becton, Dickinson and Company stock logo
BDX
Becton, Dickinson and Company
2.36
Hold$219.2227.10% Upside
DexCom, Inc. stock logo
DXCM
DexCom
2.95
Moderate Buy$98.3214.75% Upside
Insulet Co. stock logo
PODD
Insulet
2.82
Moderate Buy$318.414.17% Upside
ResMed Inc. stock logo
RMD
ResMed
2.60
Moderate Buy$259.333.31% Upside

Current Analyst Ratings Breakdown

Latest DXCM, RMD, PODD, and BDX Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
6/3/2025
Becton, Dickinson and Company stock logo
BDX
Becton, Dickinson and Company
Barclays
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOverweight ➝ Overweight$261.00 ➝ $241.00
5/30/2025
DexCom, Inc. stock logo
DXCM
DexCom
The Goldman Sachs Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy$104.00
5/30/2025
Insulet Co. stock logo
PODD
Insulet
The Goldman Sachs Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy$380.00
5/27/2025
Insulet Co. stock logo
PODD
Insulet
Raymond James
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform ➝ Outperform$328.00 ➝ $360.00
5/22/2025
Becton, Dickinson and Company stock logo
BDX
Becton, Dickinson and Company
Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeStrong-Buy ➝ Hold$217.00 ➝ $185.00
5/22/2025
DexCom, Inc. stock logo
DXCM
DexCom
Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$82.00 ➝ $102.00
5/22/2025
Insulet Co. stock logo
PODD
Insulet
Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$320.00 ➝ $380.00
5/20/2025
ResMed Inc. stock logo
RMD
ResMed
Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Set Price TargetOverweight ➝ Overweight$286.00
5/16/2025
Insulet Co. stock logo
PODD
Insulet
Sanford C. Bernstein
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform ➝ Outperform
5/13/2025
Insulet Co. stock logo
PODD
Insulet
Wolfe Research
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradePeer Perform ➝ Outperform$350.00
5/9/2025
Insulet Co. stock logo
PODD
Insulet
Oppenheimer
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOutperform ➝ Outperform$312.00 ➝ $324.00
(Data available from 6/9/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Becton, Dickinson and Company stock logo
BDX
Becton, Dickinson and Company
$20.87B2.37$16.03 per share10.76$89.57 per share1.93
DexCom, Inc. stock logo
DXCM
DexCom
$4.15B8.10$2.16 per share39.75$5.38 per share15.93
Insulet Co. stock logo
PODD
Insulet
$2.20B9.78$4.02 per share75.96$10.49 per share29.14
ResMed Inc. stock logo
RMD
ResMed
$5.02B7.33$9.95 per share25.23$35.77 per share7.02
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Becton, Dickinson and Company stock logo
BDX
Becton, Dickinson and Company
$1.71B$5.2428.6511.031.638.47%15.74%7.29%8/7/2025 (Estimated)
DexCom, Inc. stock logo
DXCM
DexCom
$576.20M$1.3459.9234.832.3014.29%30.14%10.11%7/24/2025 (Estimated)
Insulet Co. stock logo
PODD
Insulet
$206.30M$5.5652.7961.503.6220.19%24.46%8.33%8/6/2025 (Estimated)
ResMed Inc. stock logo
RMD
ResMed
$1.02B$8.9129.6424.231.5325.34%26.17%18.60%7/30/2025 (Estimated)

Latest DXCM, RMD, PODD, and BDX Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/8/2025Q1 2025
Insulet Co. stock logo
PODD
Insulet
$0.81$1.02+$0.21$0.50$543.20 million$569.00 million
5/1/2025Q2 2025
Becton, Dickinson and Company stock logo
BDX
Becton, Dickinson and Company
$3.28$3.35+$0.07$1.06$5.35 billion$5.27 billion
5/1/2025Q1 2025
DexCom, Inc. stock logo
DXCM
DexCom
$0.33$0.32-$0.01$0.27$1.02 billion$1.04 billion
4/23/2025Q3 2025
ResMed Inc. stock logo
RMD
ResMed
$2.36$2.37+$0.01$2.48$1.28 billion$1.29 billion
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Becton, Dickinson and Company stock logo
BDX
Becton, Dickinson and Company
$4.162.41%N/A79.39%53 Years
DexCom, Inc. stock logo
DXCM
DexCom
N/AN/AN/AN/AN/A
Insulet Co. stock logo
PODD
Insulet
N/AN/AN/AN/AN/A
ResMed Inc. stock logo
RMD
ResMed
$2.120.84%N/A23.79%13 Years

Latest DXCM, RMD, PODD, and BDX Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
4/29/2025
Becton, Dickinson and Company stock logo
BDX
Becton, Dickinson and Company
quarterly$1.042.02%6/9/20256/9/20256/30/2025
4/24/2025
ResMed Inc. stock logo
RMD
ResMed
quarterly$0.530.9%5/8/20255/8/20256/12/2025
(Data available from 1/1/2013 forward)
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Becton, Dickinson and Company stock logo
BDX
Becton, Dickinson and Company
0.69
1.13
0.63
DexCom, Inc. stock logo
DXCM
DexCom
0.59
1.47
1.28
Insulet Co. stock logo
PODD
Insulet
1.21
3.68
2.80
ResMed Inc. stock logo
RMD
ResMed
0.13
3.33
2.29

Institutional Ownership

CompanyInstitutional Ownership
Becton, Dickinson and Company stock logo
BDX
Becton, Dickinson and Company
86.97%
DexCom, Inc. stock logo
DXCM
DexCom
97.75%
Insulet Co. stock logo
PODD
Insulet
N/A
ResMed Inc. stock logo
RMD
ResMed
54.98%

Insider Ownership

CompanyInsider Ownership
Becton, Dickinson and Company stock logo
BDX
Becton, Dickinson and Company
0.36%
DexCom, Inc. stock logo
DXCM
DexCom
0.32%
Insulet Co. stock logo
PODD
Insulet
0.39%
ResMed Inc. stock logo
RMD
ResMed
0.71%
CompanyEmployeesShares OutstandingFree FloatOptionable
Becton, Dickinson and Company stock logo
BDX
Becton, Dickinson and Company
77,000286.61 million286.10 millionOptionable
DexCom, Inc. stock logo
DXCM
DexCom
7,600392.11 million389.60 millionOptionable
Insulet Co. stock logo
PODD
Insulet
2,60070.38 million69.82 millionOptionable
ResMed Inc. stock logo
RMD
ResMed
8,160146.63 million145.82 millionOptionable

Recent News About These Companies

ResMed Inc Reports Change in Beneficial Ownership
ResMed: A Sleeping Giant Hiding In Plain Sight
3 Cash-Heavy Stocks with Competitive Advantages

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Becton, Dickinson and Company stock logo

Becton, Dickinson and Company NYSE:BDX

$172.47 -0.98 (-0.56%)
Closing price 03:59 PM Eastern
Extended Trading
$172.90 +0.43 (+0.25%)
As of 07:39 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional. The BD Medical segment provides peripheral intravenous (IV) and advanced peripheral catheters, central lines, acute dialysis catheters, vascular access technology, vascular care and preparation products, needle-free IV connectors and extensions sets, closed-system drug transfer devices, hazardous drug detections, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, and sharps disposal systems; IV medication safety and infusion therapy delivery systems, medication compounding workflow systems, automated medication dispensing and supply management systems, and medication inventory optimization and tracking systems; and prefillable drug delivery systems. The BD Life Sciences segment offers specimen and blood collection products; automated blood and tuberculosis culturing, molecular testing, microorganism identification and drug susceptibility, and liquid-based cytology systems, as well as rapid diagnostic assays, microbiology laboratory automation products, and plated media products; and fluorescence-activated cell sorters and analyzers, antibodies and kits, reagent systems, and solutions for single-cell gene expression analysis, as well as clinical oncology, immunological, and transplantation diagnostic/monitoring reagents and analyzers. The BD Interventional segment provides hernia and soft tissue repair, biological and bioresorbable grafts, biosurgery, and other surgical products; surgical infection prevention; peripheral intervention products; and urology and critical care products. The company was founded in 1897 and is headquartered in Franklin Lakes, New Jersey.

DexCom stock logo

DexCom NASDAQ:DXCM

$85.68 -0.99 (-1.14%)
Closing price 04:00 PM Eastern
Extended Trading
$85.60 -0.09 (-0.10%)
As of 07:57 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions. It has also submitted FDA review for Dexcom Stelo for people with type 2 diabetes. The company has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop blood-based or interstitial glucose monitoring products. It markets its products directly to endocrinologists, physicians, and diabetes educators. The company was incorporated in 1999 and is headquartered in San Diego, California.

Insulet stock logo

Insulet NASDAQ:PODD

$305.66 -6.11 (-1.96%)
Closing price 04:00 PM Eastern
Extended Trading
$308.53 +2.87 (+0.94%)
As of 06:56 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours. The company sells its products primarily through independent distributors and pharmacy channels, as well as directly in the United States, Canada, Europe, the Middle East, Australia, and internationally. Insulet Corporation was incorporated in 2000 and is headquartered in Acton, Massachusetts.

ResMed stock logo

ResMed NYSE:RMD

$251.02 -1.18 (-0.47%)
Closing price 03:59 PM Eastern
Extended Trading
$250.18 -0.84 (-0.33%)
As of 06:11 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

ResMed Inc. develops, manufactures, distributes, and markets medical devices and cloud-based software applications for the healthcare markets. The company operates in two segments, Sleep and Respiratory Care, and Software as a Service. It offers various products and solutions for a range of respiratory disorders, including ApneaLink Air, a portable diagnostic device that measures oximetry, respiratory effort, pulse, nasal flow, and snoring; and NightOwl, a portable, cloud-connected, and disposable diagnostic device that measures AHI based on derived peripheral arterial tone, actigraphy, and oximetry over several nights. The company also provides AirView, a cloud-based system that enables remote monitoring and changing of patients' device settings; myAir, a personalized therapy management application for patients with sleep apnea that provides support, education, and troubleshooting tools for increased patient engagement and improved compliance; U-Sleep, a compliance monitoring solution that enables home medical equipment (HME) to streamline their sleep programs; connectivity module and propeller solutions; and Propeller portal. It offers out-of-hospital software solution, such as Brightree business management software and service solutions to providers of HME, pharmacy, home infusion, orthotics, and prosthetics services; MatrixCare care management and related ancillary solutions to senior living, skilled nursing, life plan communities, home health, home care, and hospice organizations, as well as related accountable care organizations; HEALTHCAREfirst that offers electronic health record, software, billing and coding services, and analytics for home health and hospice agencies; and MEDIFOX DAN's software solutions. The company markets its products to sleep clinics, home healthcare dealers, and hospitals through a network of distributors and direct sales force. ResMed Inc. was founded in 1989 and is headquartered in San Diego, California.